An Analytical Model of Animal Growth

The purpose of this study was to explain some aspects of ontogenetic growth in pigs by analysing the relationships between variables that are significant to the development of animals. The novelty of the study is a new modelling approach to the growth problem, with the attention that has been paid to both a new set of variables, and an analytical discrete-continuous hybrid model, innovative for the field. This is a first species-specific hybrid model for animal growth formulated in discrete-time difference equation technique. The efficiency of the model is not only due to the modelling technique but also due to a set of relevant variables, especially a feed conversion coefficient, which provides a link between macro and micro physiological scales. The model is based on functional relationships between relevant variables acquired from experimental data analyses, and field observations. The concept explains some aspects of growth in pigs from 30 kg to 600 kg, which is considered the maximum individual weight for a boar, and further growth up to a species maximum weight. The model predicts that boar can reach their maximum individual weight of 600 kg when 6,40 years old and are required to consume 62,51 kg of feed to put on the last kilogram. The phenotypes that can attain their maximum individual weight go through bifurcation of the growth trajectory, a transform in the growth mode. After bifurcation, the smallest number of the phenotypes go on the growth trajectory that leads to a set of species maximum weights of over 1205 kg, and the greatest number of phenotypes continue to live until aged 24,90 years, provided their maximum weights do not change. The study includes growth rate equations, identifies species maximum weight phenotypes, and produces insight into pig longevity. The results suggest that species maximum weight growth trajectories are phenotype-dependant. A modified discrete-time difference equation technique combined with standard continuum methods is an appropriate formalism to model ontogenetic growth in animals

Erythroleukemia Relapsing as Precursor B-cell Lymphoblastic Leukemia

AML relapsing as ALL has rarely been reported. We describe the case of a 62-yr-old man who was diagnosed with erythroleukemia with a complex karyotype and achieved complete hematologic and cytogenetic remission after induction chemotherapy. However, 4 months after the initial diagnosis, he showed relapse with blasts showing a different morphology and immunophenotype and was diagnosed with precursor B-cell ALL. The relapsing precursor B-cell ALL presented with the same leukemic clones as the primary erythroleukemia. Cytogenetic analysis of his bone marrow (BM) at the time of the primary erythroleukemia showed complex karyotypic abnormalities, including monosomy 5 and monosomy 7. At relapse, his BM showed reemergence of these leukemic clones of complex karyotypic abnormalities with clonal switch. To our knowledge, this is the first case of a lineage switch from erythroleukemia to ALL

Myeloid sarcomas: a histologic, immunohistochemical, and cytogenetic study

This is an Open Access article distributed under the terms of the Creative Commons Attribution Licens

Synthesis of nitroxyl radical by direct nucleophilic functionalization of a C-H bond in the azadiene systems

Cyclic dinitrones underwent nucleophilic substitution of the hydrogen atom in the reaction with a paramagnetic carbanion, the lithium derivative of 4,4,5,5-tetramethyl-4,5-dihydro-1H-imidazol-1-oxyl 3-oxide, to give polyfunctional nitronyl nitroxyls. © 2012 Springer Science+Business Media New York

Biopharmaceutical Characteristics of Nifurtimox Tablets for Age- and Body Weight-Adjusted Dosing in Patients With Chagas Disease.

Treatment of Chagas disease with nifurtimox requires age- and body weight-adjusted dosing, resulting in complex dosing instructions. Appropriate formulations are needed for precise and compliant dosing, especially in pediatric patients. We characterized the biopharmaceutical features of a standard nifurtimox 120-mg tablet and a 30-mg tablet developed to improve dose accuracy. Two open-label, randomized crossover studies were conducted in adult outpatients with Chagas disease. One study investigated whether 4 × 30-mg tablets and 1 × 120-mg tablet were bioequivalent and whether tablets can be administered as an aqueous slurry without affecting bioavailability. The second study investigated the effect of a high-calorie/high-fat diet versus fasting on the absorption of nifurtimox after a single 4 × 30-mg dose. Interventions were equivalent if the 90% confidence interval (CI) of their least-squares (LS) mean ratios for both AU

A comparative study of optical properties and X-ray induced luminescence of octahedral molybdenum and tungsten cluster complexes

© 2017 The Royal Society of Chemistry. Octahedral metal cluster complexes have high potential for biomedical applications. In order to evaluate the benefits of these moieties for combined CT/X-ray luminescence computed tomography, this paper compares photoluminescence, radiodensity and X-ray induced luminescence properties of eight related octahedral molybdenum and tungsten cluster complexes [{M 6 I 8 }L 6 ] n (where M is Mo or W and L is I - , NO 3 - , OTs - or OH - /H 2 O). This article demonstrates that despite the fact that molybdenum cluster complexes are better photoluminescence emitters, tungsten cluster complexes, in particular (Bu 4 N) 2 [{W 6 I 8 }I 6 ], demonstrate significantly higher X-ray induced luminescence due to a combination of relatively good photoluminescence properties and high X-ray attenuation. Additionally, photo-degradation of [{M 6 I 8 }(NO 3 ) 6 ] 2- was evaluated

Beyond structures of highly symmetric purified viral capsids by cryo-EM

Cryogenic transmission electron microscopy (cryo-EM) is widely used to determine high-resolution structures of symmetric virus capsids. The method holds promise for extending studies beyond purified capsids and their symmetric protein shells, The non-symmetric genome component has been addressed in dsRNA cypoviruses and ssRNA bacteriophages Q beta and MS2. The structure of human herpes simplex virus type 1 capsids has been determined within intact virions to resolve capsid-tegument interactions. Electron tomography under cryogenic conditions (cryo-ET), has allowed resolving an early membrane fusion intermediate of Rift Valley fever virus. Antibody-affinity based sample grids allow capturing of virions directly from cell cultures or even clinical samples. These and other emerging methods will support studies to address viral entry, assembly and neutralization processes at increasingly high resolutions and native conditions.Peer reviewe

Selective release of muscle-specific, extracellular microRNAs during myogenic differentiation

MyomiRs are muscle-specific microRNAs (miRNAs) that regulate myoblast proliferation and differentiation. Extracellular myomiRs (ex-myomiRs) are highly enriched in the serum of Duchenne Muscular Dystrophy (DMD) patients and dystrophic mouse models and consequently have potential as disease biomarkers. The biological significance of miRNAs present in the extracellular space is not currently well understood. Here we demonstrate that ex-myomiR levels are elevated in perinatal muscle development, during the regenerative phase that follows exercise-induced myoinjury, and concomitant with myoblast differentiation in culture. Whereas ex-myomiRs are progressively and specifically released by differentiating human primary myoblasts and C2C12 cultures, chemical induction of apoptosis in C2C12 cells results in indiscriminate miRNA release. The selective release of myomiRs as a consequence of cellular differentiation argues against the idea that they are solely waste products of muscle breakdown, and suggests they may serve a biological function in specific physiological contexts. Ex-myomiRs in culture supernatant and serum are predominantly non-vesicular, and their release is independent of ceramide-mediated vesicle secretion. Furthermore, ex-myomiRs levels are reduced in aged dystrophic mice, likely as a consequence of chronic muscle wasting. In conclusion, we show that myomiR release accompanies periods of myogenic differentiation in cell culture and in vivo. Serum myomiR abundance is therefore a function of the regenerative/degenerative status of the muscle, overall muscle mass, and tissue expression levels. These findings have implications for the use of ex-myomiRs as biomarkers for DMD disease progression and monitoring response to therapy

Moxifloxacin in Pediatric Patients With Complicated Intra-abdominal Infections: Results of the MOXIPEDIA Randomized Controlled Study

Background: This study was designed to evaluate primarily the safety and also the efficacy of moxifloxacin (MXF) in children with complicated intraabdominal infections (cIAIs). Methods: In this multicenter, randomized, double-blind, controlled study, 451 pediatric patients aged 3 months to 17 years with cIAIs were treated with intravenous/oral MXF (N = 301) or comparator (COMP, intravenous ertapenem followed by oral amoxicillin/clavulanate; N = 150) for 5 to 14 days. Doses of MXF were selected based on the results of a Phase 1 study in pediatric patients (NCT01049022). The primary endpoint was safety, with particular focus on cardiac and musculoskeletal safety; clinical and bacteriologic efficacy at test of cure was also investigated. Results: The proportion of patients with adverse events (AEs) was comparable between the 2 treatment arms (MXF: 58.1% and COMP: 54.7%). The incidence of drug-related AEs was higher in the MXF arm than in the COMP arm (14.3% and 6.7%, respectively). No cases of QTc interval prolongation-related morbidity or mortality were observed. The proportion of patients with musculoskeletal AEs was comparable between treatment arms; no drug-related events were reported. Clinical cure rates were 84.6% and 95.5% in the MXF and COMP arms, respectively, in patients with confirmed pathogen(s) at baseline. Conclusions: MXF treatment was well tolerated in children with cIAIs. However, a lower clinical cure rate was observed with MXF treatment compared with COMP. This study does not support a recommendation of MXF for children with cIAIs when alternative more efficacious antibiotics with better safety profile are available